We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01240447
Recruitment Status : Completed
First Posted : November 15, 2010
Last Update Posted : July 10, 2014
Sponsor:
Information provided by (Responsible Party):
Laboratorio Elea Phoenix S.A.

Tracking Information
First Submitted Date  ICMJE September 23, 2010
First Posted Date  ICMJE November 15, 2010
Last Update Posted Date July 10, 2014
Study Start Date  ICMJE September 2009
Actual Primary Completion Date August 2012   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 16, 2010)
  • Number of Participants with Adverse events as a measure of safety and tolerability [ Time Frame: Until death, on average during 17 months ]
    Safety will be evaluated at each study visit according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 and will include physical examination with vital signs, performance status as per the Eastern Cooperative Oncology Group scale(ECOG scale), laboratory tests and clinical history.
  • Evaluation of the reactivity if the antibodies against X63 tumor line [ Time Frame: Baseline ]
  • Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry. [ Time Frame: Baseline ]
  • Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available) [ Time Frame: Baseline ]
  • Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay. [ Time Frame: Baseline ]
  • Measurement of pro-inflammatory and anti-inflammatory cytokines [ Time Frame: Baseline ]
  • Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry. [ Time Frame: Month 2 ]
  • Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry. [ Time Frame: Month 4 ]
  • Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry. [ Time Frame: Month 8 ]
  • Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry. [ Time Frame: Month 12 ]
  • Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside [ Time Frame: Baseline ]
  • Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available) [ Time Frame: Month 2 ]
  • Measurement of pro-inflammatory and anti-inflammatory cytokines. [ Time Frame: Baseline ]
  • Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside [ Time Frame: Month 2 ]
  • Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside [ Time Frame: Month 8 ]
  • Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside [ Time Frame: Month 4 ]
  • Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside [ Time Frame: Month 12 ]
  • Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside [ Time Frame: Every 4 months (after the first year, on average during 17 months) ]
  • Evaluation of the reactivity if the antibodies against X63 tumor line [ Time Frame: Month 2 ]
  • Evaluation of the reactivity if the antibodies against X63 tumor line [ Time Frame: Month 12 ]
  • Evaluation of the reactivity if the antibodies against X63 tumor line [ Time Frame: Every 4 months (after the first year, on average during 17 months) ]
  • Evaluation of the reactivity if the antibodies against X63 tumor line [ Time Frame: Month 4 ]
  • Evaluation of the reactivity if the antibodies against X63 tumor line [ Time Frame: Month 8 ]
  • Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available) [ Time Frame: Month 4 ]
  • Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available) [ Time Frame: Month 8 ]
  • Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available) [ Time Frame: Month 12 ]
  • Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available) [ Time Frame: Every 4 months (after the first year, on average during 17 months) ]
  • Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay. [ Time Frame: Month 2 ]
  • Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay. [ Time Frame: Month 4 ]
  • Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay. [ Time Frame: Month 8 ]
  • Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay. [ Time Frame: Month 12 ]
  • Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay. [ Time Frame: Every 4 months (after the first year, on average during 17 months) ]
  • Measurement of pro-inflammatory and anti-inflammatory cytokines [ Time Frame: Month 2 ]
  • Measurement of pro-inflammatory and anti-inflammatory cytokines [ Time Frame: Month 4 ]
  • Measurement of pro-inflammatory and anti-inflammatory cytokines [ Time Frame: Month 8 ]
  • Measurement of pro-inflammatory and anti-inflammatory cytokines [ Time Frame: Month 12 ]
  • Measurement of pro-inflammatory and anti-inflammatory cytokines [ Time Frame: Every 4 months (after the first year, on average during 17 months) ]
Original Primary Outcome Measures  ICMJE
 (submitted: November 12, 2010)
  • Number of Participants with Adverse events as a measure of safety and tolerability [ Time Frame: Until death, on average during 17 months ]
    Safety will be evaluated at each study visit according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 and will include physical examination with vital signs, performance status as per the Eastern Cooperative Oncology Group scale(ECOG scale), laboratory tests and clinical history.
  • Evaluation of the reactivity if the antibodies against X63 tumor line [ Time Frame: Baseline ]
  • Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry. [ Time Frame: Baseline ]
  • Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available) [ Time Frame: Baseline ]
  • Determination of gamma interferon by ELISPOT [ Time Frame: Baseline ]
  • Measurement of pro-inflammatory and anti-inflammatory cytokines [ Time Frame: Baseline ]
  • Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry. [ Time Frame: Month 2 ]
  • Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry. [ Time Frame: Month 4 ]
  • Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry. [ Time Frame: Month 8 ]
  • Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry. [ Time Frame: Month 12 ]
  • Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside [ Time Frame: Baseline ]
  • Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available) [ Time Frame: Month 2 ]
  • Measurement of pro-inflammatory and anti-inflammatory cytokines. [ Time Frame: Baseline ]
  • Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside [ Time Frame: Month 2 ]
  • Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside [ Time Frame: Month 8 ]
  • Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside [ Time Frame: Month 4 ]
  • Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside [ Time Frame: Month 12 ]
  • Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside [ Time Frame: Every 4 months (after the first year, on average during 17 months) ]
  • Evaluation of the reactivity if the antibodies against X63 tumor line [ Time Frame: Month 2 ]
  • Evaluation of the reactivity if the antibodies against X63 tumor line [ Time Frame: Month 12 ]
  • Evaluation of the reactivity if the antibodies against X63 tumor line [ Time Frame: Every 4 months (after the first year, on average during 17 months) ]
  • Evaluation of the reactivity if the antibodies against X63 tumor line [ Time Frame: Month 4 ]
  • Evaluation of the reactivity if the antibodies against X63 tumor line [ Time Frame: Month 8 ]
  • Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available) [ Time Frame: Month 4 ]
  • Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available) [ Time Frame: Month 8 ]
  • Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available) [ Time Frame: Month 12 ]
  • Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available) [ Time Frame: Every 4 months (after the first year, on average during 17 months) ]
  • Determination of gamma interferon by ELISPOT [ Time Frame: Month 2 ]
  • Determination of gamma interferon by ELISPOT [ Time Frame: Month 4 ]
  • Determination of gamma interferon by ELISPOT [ Time Frame: Month 8 ]
  • Determination of gamma interferon by ELISPOT [ Time Frame: Month 12 ]
  • Determination of gamma interferon by ELISPOT [ Time Frame: Every 4 months (after the first year, on average during 17 months) ]
  • Measurement of pro-inflammatory and anti-inflammatory cytokines [ Time Frame: Month 2 ]
  • Measurement of pro-inflammatory and anti-inflammatory cytokines [ Time Frame: Month 4 ]
  • Measurement of pro-inflammatory and anti-inflammatory cytokines [ Time Frame: Month 8 ]
  • Measurement of pro-inflammatory and anti-inflammatory cytokines [ Time Frame: Month 12 ]
  • Measurement of pro-inflammatory and anti-inflammatory cytokines [ Time Frame: Every 4 months (after the first year, on average during 17 months) ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 12, 2010)
  • Survival [ Time Frame: Until date of death or last censored observation ]
    On average, during 17 months
  • Progression free survival [ Time Frame: Until first progression of disease ]
    Tumour evaluations will be performed every 2 months and evaluated as per Response Evaluation Criteria in Solid Tumors (RECIST).
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients
Official Title  ICMJE A Prospective, Randomised, Open Label Phase II Study of Active Specific Immunotherapy With Racotumomab Versus Support Treatment in Patients With Advanced Non-small Cell Lung Cancer
Brief Summary This study is designed to evaluate safety and immunogenicity of racotumomab in patients with advanced Non-small Cell Lung Cancer (NSCLC), in concomitance with chemotherapy (docetaxel) when a second-line therapy is indicated. The study will also compare survival and progression free survival on both study arms.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Advanced Non-small Cell Lung Cancer
Intervention  ICMJE
  • Biological: racotumomab
    Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), subcutaneously, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and a second line therapy is indicated, the patient will only be able to continue in the study if the drug indicated is docetaxel. Vaccination will not be interrupted during docetaxel administration unless criteria for vaccine discontinuation are met.
    Other Name: 1E10
  • Other: Best support treatment
    Patients will receive best support treatment as indicated by the investigator. In case a second line therapy is indicated, docetaxel is the only drug allowed to continue in the study.
Study Arms  ICMJE
  • Best support treatment
    Intervention: Other: Best support treatment
  • Experimental: Racotumomab vaccine
    Intervention: Biological: racotumomab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 9, 2014)
7
Original Estimated Enrollment  ICMJE
 (submitted: November 12, 2010)
30
Actual Study Completion Date  ICMJE June 2014
Actual Primary Completion Date August 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. The patient (aged over 21 years, either sex) can comply with the protocol and scheduled appointments and sign voluntarily the informed consent form
  2. Diagnosis of Non-small cell lung cancer (NSCLC) stages IIIA (surgically unresectable), IIIB or IV, according to the TNM classification (Tumor-Nodes-Metastases) version 6a, confirmed by cytology or histology, if possible available for determination of ganglioside expression
  3. Patients may enter the study if they have accomplished an objective response (complete response or partial response) or disease stabilisation (by Response Evaluation Criteria In Solid Tumours [RECIST]) after completion of standard onco-specific treatment. In all cases, response should be documented.

    For stage IIIA and IIIB without pleural effusion ("dry IIIB") standard treatment is considered as follows: 2 - 4 cycles of platinum-based chemotherapy and/or radiotherapy with curative intent in accordance with National Comprehensive Cancer Network (NCCN) guidelines For stage IIIB with pleural effusion ("wet IIIB") and stage IV standard treatment is considered as follows: 4 - 6 cycles of chemotherapy based on platinum. In case of pleural or pericardial effusion requiring local treatment, it will be provided prior to study entry.

  4. Patients with an interval greater than 30 and not more than 90 days between the completion of oncospecific treatment and study entry. Completion of treatment is defined as the last day of administration of chemotherapy or the last day of radiotherapy. Patients should have recovered from any related episode of acute toxicity of degree greater than 1 (except alopecia). Patients who have received a monoclonal antibody (eg bevacizumab) should also have discontinued its use for at least 30 days before inclusion.
  5. The subject is male or female, aged greater than or equal to 21 years
  6. Performance status (Eastern Cooperative Oncology Group [ECOG]) less than or equal to 1
  7. Acceptable organ functionality as defined by the following parameters:

    • Electrocardiogram (ECG) without significant abnormalities, performed within 14 days prior to admission
    • Haemoglobin greater than or equal to 90 g/L
    • Total leukocyte count greater than or equal to 3.0 x 10^9/L
    • Absolute neutrophil count greater than or equal to 1.5 x 10^9/L
    • Total bilirubin less than or equal to 1.5 times upper limit of normal or twice the limit normal than in case liver metastases are present
    • Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) less than or equal to 2.5 times upper limit of normal (less than or equal to five times the normal maximum in case liver metastases are present)
    • Creatinine less than or equal to 2 mg/dL
  8. Life expectancy of at least four months

Exclusion Criteria:

  1. Patient is pregnant or breastfeeding
  2. Has received chemotherapy, radiotherapy, immunotherapy or surgery within 30 days prior to inclusion
  3. Hypersensitivity to any component of the formulation
  4. Patients of childbearing potential of either sex who are not using an adequate method of contraception during treatment to avoid pregnancy (own or of partner). For females: intrauterine devices, hormonal contraceptives, barrier methods or sterilisation. For males: vasectomy or condoms with spermicide.
  5. Patients receiving or having received other investigational drugs 30 days prior to study entry
  6. History of autoimmune diseases
  7. Decompensated chronic diseases
  8. Acute allergic disorders or history of severe allergic reactions
  9. Known brain metastases uncontrolled with surgery and/or radiation therapy or under current corticosteroid therapy
  10. History of inflammatory or demyelinating disease of the central or peripheral nervous system
  11. Uncontrolled intercurrent illnesses, including active infection, symptomatic congestive heart failure, unstable angina or cardiac arrhythmia and psychiatric diseases implying patient incompetence
  12. Other malignancies, with the exception of basal cell carcinoma, in situ cervical carcinoma, incidental prostate cancer (T1a, Gleason less than or equal to 6, prostate specific antigen [PSA] less than 0.5 ng/ml), tumour or any other tumour adequately treated and with a disease-free period greater than or equal to 5 years
  13. Chronic treatment with systemic corticosteroids at doses greater than 0.5 mg/kg/day or a maximum of 40 mg/day of prednisone or equivalent
  14. The subject has a history of drug abuse (illicit drugs) or alcohol abuse (defined as regular or periodic ingestion of more than four drinks a day) in the last 2 years
  15. Positive serology for hepatitis B, C or known human immunodeficiency virus (HIV) infection
  16. Uncontrolled hypercalcaemia greater than or equal to 2.9 mmol/L (or grade greater than 1 according to the Common Terminology Criteria for Adverse Events [CTCAE] version 3.0)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 21 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01240447
Other Study ID Numbers  ICMJE AR-RACO-02-08
ISRCTN47153584 ( Registry Identifier: Intl Standard Randomised Controlled Trial Number Register )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Laboratorio Elea Phoenix S.A.
Original Responsible Party Dr. Laura Ardigó, Laboratorio Elea S.A.C.I.F. y A.
Current Study Sponsor  ICMJE Laboratorio Elea Phoenix S.A.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Gabriela Cinat, MD Instituto de Oncología "Angel H. Roffo"
PRS Account Laboratorio Elea Phoenix S.A.
Verification Date July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP